Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
RemAb Therapeutics logo — Removing harmful antibodies.

RemAb Therapeutics

Removing harmful antibodies.

Founded 2018 Spain Spain 8 employees Grant Total: $71.43K Biotechnology, Health Care

General Information

Company Name RemAb Therapeutics
Founded Year 2018
Location Spain Spain +1
Founders / Decision Makers
Team member Team member
Employees 8
Industries Biotechnology, Health Care
Funding Stage Grant
Social

Get notified when RemAb Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About RemAb Therapeutics

RemAb Therapeutics is a biopharmaceutical company founded in 2018 with a focus on removing harmful antibodies. The company's expertise lies in the identification, characterization, and selective removal of specific antibodies using their proprietary HART-Technology. With a strong presence in Spain, RemAb Therapeutics operates in the biotechnology and healthcare industries, offering solutions in infectious diseases, allergology, autoimmunity, transplantation and transfusion medicine, as well as the modulation of human immune responses against viral vectors.

Having secured a $71.43K grant investment on 01 January 2019, RemAb Therapeutics has garnered support from notable investors such as EASME - EU Executive Agency for SMEs. The company's innovative approach to targeting specific antibodies and its diverse applications in healthcare make it a promising venture for potential investors in the biopharmaceutical sector.

Taxonomy: Biopharmaceuticals, Polymeric Glycoconjugates, Nosocomial Infections, Gram-negative Infections, Healthcare Innovation, Drug Development, Immunotherapy, Antibody Treatment, Preclinical Research, Barcelona, Therapeutics, Global Commercialization, Infection Control, Immune System Modulation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 01 Jan 2019
Grant •••••• 1 •••• •••• 19 Sep 2018

RemAb Therapeutics Alternatives & Competitors

RemAb Therapeutics vs
Curetis GmbH
Curetis GmbH Germany

Fast & Simple Syndromic PCR Testing for Severe Infections - Improving Patient Outcomes

Post Ipo Debt
28 employees
Biotechnology
RemAb Therapeutics vs
Novatec Immundiagnostica
Novatec Immundiagnostica

Innovative solutions for accurate diagnostics and exceptional support every step of the way

51-200 employees
Biotechnology, Health Care
RemAb Therapeutics vs
Fimbrion Therapeutics, Inc.
Fimbrion Therapeutics, Inc. United States

Antibiotic-sparing approaches to fight acute and resistant infections caused by bacteria and other p...

6 employees
Health Care

FAQ About RemAb Therapeutics

Removing harmful antibodies.
RemAb Therapeutics was founded in 2018.
RemAb Therapeutics is headquartered in Spain.
RemAb Therapeutics operates in the following industries: Biotechnology, Health Care.
RemAb Therapeutics has approximately 8 employees.
RemAb Therapeutics has completed 2 funding rounds, raising a total of $71.43K. The latest funding stage is Grant.
Top alternatives and competitors to RemAb Therapeutics include Curetis GmbH, Novatec Immundiagnostica, Fimbrion Therapeutics, Inc., Akthelia Pharmaceuticals, Synereca Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
RemAb Therapeutics and Curetis GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors RemAb Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy